L. E. Lantry, Z. Zhang, D. Hu, R. Yao, F. Gao, K. A. Crist, J. Ohkanda, A. D. Hamilton, S. M. Sebti, G. J. Kelloff, R. A. Lubet, and M. You.
Effect of the farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Carcinogenesis 2000, 21(1), 113-116.
DOI: 10.1093/carcin/21.1.113
K. Jiang, D. Coppola, N. C. Crespo, S. V. Nicosia, A. D. Hamilton, S. M. Sebti, and J. Q. Cheng.
The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis.
Molecular and Cellular Biology 2000, 20(1), 139-148.
DOI: 10.1128/MCB.20.1.139-148.2000
V. Carloni, M. Pinzani, S. Giusti, R. G. Romanelli, M. Parola, G. Bellomo, P. Failli, A. D. Hamilton, S. M. Sebti, G. Laffi, and P. Gentilini.
Tyrosine phosphorylation of focal point adhesion kinase by PDGF is dependent on Ras in human hepatic stellate cells.
Hepatology 2000, 31(1), 131-140.
DOI: 10.1002/hep.510310121
E. J. Bernhard, R. J. Muschel, E. Cohen-Jonathan, G. Favre, A. D. Hamilton, and S. M. Sebti.
Prenyltransferase inhibitors as radiosensitizers.
In A. D. Hamilton and S. M. Sebti, editors, Farnesyltransferase as a Target in Anti-Cancer Drug Design, page 171. Humana Press, 2000.
B. Linton, M. S. Goodman, and A. D. Hamilton.
Nitronate anion recognition and modulation of ambident reactivity by hydrogen-bonding receptors.
Chemistry- A European Journal 2000, 6(13), 2449-2455.
DOI: 10.1002/1521-3765(20000703)6:13<2449::AID-CHEM2449>3.0.CO;2-9
B. R. Linton, A. J. Carr, B. P. Orner, and A. D. Hamilton.
A versitile one-pot synthesis of 1,3-substituted guanidines from carbamoyl-isothiocyanates.
Journal of Organic Chemistry 2000, 65(5), 1566-1568.
DOI: 10.1021/jo991458q
M. W. Peczuh and A. D. Hamilton.
Peptide and protein recognition by designed molecules.
Chemical Reviews 2000, 100(7), 2479-2493.
DOI: 10.1021/cr9900026
R. E. Melendez, A. J. Carr, B. R. Linton, and A. D. Hamilton.
Controlling hydrogen bonding: From molecular recognition to organogelation.
Topics in Current Chemistry 2000, 96, 31-61.
M. J. Gelb, F. S. Buckner, K. Yokoyama, J. Ohkanda, A. D. Hamilton, L. Nguyen, S. M. Sebti, and W. C. Van Voorhis.
Protein prenylation in trypanosomatids: A new piggy-back medicinal chemistry target for the development of agents against tropical diseases.
In Drugs Against Parasitic Diseases, number 2000, page 0000, France.
U. Kucich, J. C. Rosenblum, G. Shen, W. R. Abrams, A. D. Hamilton, S. M. Sebti, and J. Rosenbloom.
Tgf-β stimulation of fibronectin transcription in cultured human lung fibroblasts requires active geranylgeranyltransferase I, phosphatidylcholine-specific phospholipase C, protein kinase c-δ, and p38, but not erk1/erk2.
Archives of Biochemistry and Biophysics 2000, 374(2), 313-324.
DOI: 10.1006/abbi.1999.1625
E. Cohen-Jonathan, R. J. Muschel, W. G. McKenna, S. Evans, G. Cerniglia, R. Mick, D. Kusewitt, S. M. Sebti, A. D. Hamilton, A. Oliff, N. Kohl, J. B. Gibbs, and E. J. Bernhard.
Farnesyltransferase inhibitors potentiate the antitumor effects of radiation on a human tumor xenograft expressing activated HRas.
Radiation Research 2000, 154(2), 125-132.
DOI: 10.1667/0033-7587(2000)154[0125:FIPTAE]2.0.CO;2
A. Boota, B. A. Johnson, K. I. Lee, M. A. Blaskovich, A. D. Hamilton, B. Pitt, S. M. Sebti, and P. Davies.
Prenyltransferase inhibitors block superoxide production by pulmonary vascular smooth muscle.
American Journal of Physiology 2000, 278(2, pt 1), L329-L334.
D. Knowles, S. Rosenberg, S. M. Sebti, and A. D. Hamilton.
Peptidomimetic-based inhibitors of farnesyltransferase.
In S. M. Sebti and A. D. Hamilton, editors, Farnesyltransferase as a Target in Anti-Cancer Drug Design, page 49. Humana Press, 2000.
A. Zafar, S. J. Geib, Y. Hamuro, A. J. Carr, and A. D. Hamilton.
Hydrogen bonding control of molecular self-assembly: Aggregation behavior of acylaminopyridine-carboxylic acid derivatives in solution and the solid state.
Tetrahedron 2000, 56(43), 8419-8427.
DOI: 10.1016/S0040-4020(00)00733-X
M. J. Gelb, F. S. Bruckner, K. Yokoyama, J. Ohkanda, A. D. Hamilton, L. Nguyen, B. Rossi-Bergmann, K. D. Stuart, S. M. Sebti, and W. C. Van Voorhis.
Protein prenylation in trypanosomatids: A new piggy-back medicinal chemistry target for the development of agents against tropical diseases.
In S. M. Sebti and A. D. Hamilton, editors, Farnesyltransferase as a Target in Anti-Cancer Drug Design, page 221. Humana Press, 2000.
R. E. Melendez, A. J. Carr, K. Sada, and A. D. Hamilton.
The design of organic gelators based on a family of bis-ureas.
In M. Wun-Fogle, K. Uchino, Y. Ito, and R. Gotthardt, editors, Materials for Smart Systems III, page 335, 2000.
J. Adnane, F. A. Bizouarn, Z. Chen, T. Munoz-Antonia, J. Ohkanda, A. D. Hamilton, and S. M. Sebti.
Inhibition of farnesyltransferase increases TGFβ type II receptor expression and enhances the responsiveness of human cancer cells to TGFβ.
Oncogene 2000, 19(48), 5525-5533.
S. M. Sebti and A. D. Hamilton.
Farnesyltransferase and geranylgeranyltransferase i inhibitors as novel agents for cancer and cardiovascular diseases.
In S. M. Sebti and A. D. Hamilton, editors, Farnesyltransferase as a Target in Anti-Cancer Drug Design, page 197. Humana Press, 2000.
J. Rosenbloom, B. Saitta, S. Gaidarova, N. Sandorfi, J. C. Rosenbloom, W. R. Abrams, A. D. Hamilton, S. M. Sebti, U. Kucich, and S. A. Jimenez.
Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyltransferase I.
Arthritis and Rheumatism 2000, 42(7), 1624-1632.
DOI: 10.1002/1529-0131(200007)43:7<1624::AID-ANR28>3.0.CO;2-E
S. M. Sebti and A. D. Hamilton.
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanistic and bench-to-bedside translational studies.
Oncogene 2000, 19(56), 6584-6593.
S. M. Sebti and A. D. Hamilton.
Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitors.
Methods in Enzymology 2000, 325, 381-388.
DOI: 10.1016/S0076-6879(00)25459-1
X. Salvatella, M. Peczuh, M. Gairi, R. Jain, J. Sanchez-Quesada, J. de Mendoza, A. D. Hamilton, and E. Giralt.
Side chain length dependent thermodynamics of α-helical peptide recognition.
Journal of the Chemical Society, Chemical Communications 2000, pages 1399-1400.
DOI: 10.1039/B003728L
M. A. Blaskovich, Q. Lin, F. L. Delarue, J. Sun, H. S. Park, D. Coppola, A. D. Hamilton, and S. M. Sebti.
Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice.
Nature Biotechnology 2000, 18(10), 1065-1070.
DOI: 10.1038/80257
C. Allal, G. Favre, B. Couderc, S. Sixou, A. D. Hamilton, S. M. Sebti, and A. Pradines.
Rhoa prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription.
Journal of Biological Chemistry 2000, 275(40), 31001-31008.
DOI: 10.1074/jbc.M005264200
M. Peczuh, B. Orner, and A. D. Hamilton.
In recognition of proteins.
Chemistry in Britain 2000, 36(8), 43-45.
L. Ghosh, A. D. Hamilton, and L. Regan.
Antiparallel leucine zipper-directed protein reassembly: Application to the green fluorescent protein.
Journal of the American Chemical Society 2000, 122(23), 5658-5689.
DOI: 10.1021/ja994421w
R. Jain and A. D. Hamilton.
Protein surface recognition by synthetic receptors based on a tetraphenylporphyrin scaffold.
Organic Letters 2000, 2(12), 1721-1723.
DOI: 10.1021/ol005871s
L. Estroff and A. D. Hamilton.
Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitors.
Angewandte Chemie International Edition 2000, 39(19), 3447-3450.
DOI: 10.1002/1521-3773(20001002)39:19<3447::AID-ANIE3447>3.0.CO;2-X
M. A. Koutare, J. Ohkanda, J. W. Lockman, Y. Qian, M. A. Blaskovich, S. M. Sebti, and A. D. Hamilton.
Development of a tripeptide mimetic strategy for the inhibition of protein farnesyltransferase.
Tetrahedron 2000, 56(50), 9833-9841.
DOI: 10.1016/S0040-4020(00)00890-5
F. P. Coxon, M. H. Helfrich, R. Van't Hof, S. M. Sebti, S. H. Ralston, A. D. Hamilton, and M. J. Rogers.
Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298.
Journal of Bone and Mineral Research 2000, 15(8), 1467-1476.
DOI: 10.1359/jbmr.2000.15.8.1467
S. M. Sebti and A. D. Hamilton.
Farnesyltransferase and geranylgeranyltransferase i inhibitors as novel agents for cancer and cardiovascular diseases.
Expert Opinion on Investigational Drugs 2000, 9(12), 2767-2782.
S. Wei, D. K. Gilvary, B. C. Corliss, S. M. Sebti, J. Sun, D. B. Straus, P. J. Leibson, J. A. Trapani, A. D. Hamilton, M. J. Weber, and J. Y. Djeu.
Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway.
Journal of Immunology 2000, 165(7), 3811-3819.
S. M. Sebti and A. D. Hamilton.
Design of growth factor antagonists with antiangiogenic and antitumor properties.
Oncogene 2000, 19(56), 6566-6573.